Type 2 diabetes mellitus has been reported during antipsychotic treatment.
Objective:
To quantify the potential risk of treatment-emergent diabetes mellitus among patients receiving antipsychotic medications.
Methods:
The MEDLINE and Psychinfo databases were searched using the key words antipsychotic (including individual drug names), diabetes, risk, and incidence for all English-language articles published between 1966 and 2005. Risk calculations were performed using data obtained from pharmacoepidemiologic studies that met the following criteria: (1) cohort design, (2) determination of preexisting diabetes, (3) inclusion of antipsychotic monotherapy as an exposure variable, and (4) comparison with exposure to first-generation antipsychotics. Studies meeting these criteria were used to calculate incidence, attributable risk between agents, and number needed to harm.
Results:
A total of 25 observational pharmacoepidemiologic studies were found comparing antipsychotics on the outcome of diabetes mellitus. Sufficient information was provided in 15 of the reports to be able to estimate attributable risk, Attributable risk for individual second-generation antipsychotics relative to first-generation antipsychotics ranged from 53 more to 46 fewer new cases of diabetes per 1000 patients. Little observable difference was noted between the individual second-generation antipsychotics versus first-generation antipsychotics on this outcome. However, few of the studies controlled for body weight, race or ethnicity, or the presence of diabetogenic medications. None adjusted for familial history of diabetes, levels of physical activity, or diet, as this information is not usually available in the databases used in pharmacoepidemiologic studies.
Conclusions:
Based on the published pharmacoepidemiologic reports reviewed, the avoidance of diabetes as an outcome cannot be predictably achieved with precision by choice of a second- versus a first-generation antipsychotic. Risk management for new-onset diabetes requires the assessment of established risk factors such as family history, advancing age, non-white ethnicity, diet, central obesity, and level of physical activity.
TarsyD, BaldessariniRJ, TaraziFI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs2002;16:23–45.
2.
LorenzWF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry1922;8:184–96.
3.
MarderSR, EssockSM, MillerAL, . Physical health monitoring of patients with schizophrenia. Am J Psychiatry2004;161:1334–49.
4.
CitromeL.The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today2004;40:445–64.
5.
LindenmayerJP, CzoborP, VolavkaJ, . Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry2003;160:290–6.
6.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care2004; 27:596–601.
7.
RacoosinJA, FeeneyJ, BurkhartG, BoehmG.Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care2004;27:2088–9.
8.
EtminanM.Pharmacoepidemiology II: the nested case-control study—a novel approach in pharmacoepidemiologic research. Pharmacotherapy2004;24:1105–9.
9.
EtminanM, SamiiA.Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacotherapy2004;24:964–9.
10.
BarnerJC, WorchelJ, YangM.Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among central Texas veterans. Pharmacotherapy2004;24:1529–38.
11.
LeslieDL, RosenheckR.Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry2004;161:1709–11.
12.
OstbyeT, CurtisLH, MasselinkLE, . Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf2005;14:407–15.
13.
SacchettiE, TurrinaC, ParrinelloG, . Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol2005;20:33–7.
14.
BuseJB, CavazzoniP, HornbuckleK, . A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol2003;56:164–70.
15.
FeldmanPD, HayLK, KennedyJS, . Retrospective cohort study of diabetes mellitus and antipsychotic treatment in geriatric population in the United States. J Am Med Dir Assoc2004;5:38–46.
16.
MillerEA, LeslieDL, RosenheckRA. Incidence of new onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis2005;193:387–95.
17.
MoisanJ, GregoireJP, GaudetM, . Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf2005;14:427–36.
18.
OllendorfDA, JoyceAT, RuckerM.Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med2004;6:5. www.medscape.com/viewarticle/466800 (accessed 2006 Nov 3).
19.
ZhaoZ, TunisSL, LoosbrockDL. Risk of diabetes for individuals with schizophrenia treated with antipsychotics. J Applied Res2002;3:287–95.
20.
CaroJ, WardA, LevingtonC, . The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry2002;63:1135–9.
21.
EtminanM, StreinerDL, RochonPA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy2003;23:1411–5.
22.
FarwellWR, StumpTE, WangJ, . Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med2004;19:1200–5.
23.
FullerMA, ShermockKM, SecicM, . Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy2003;23:1037–43.
24.
GianfrancescoFD, GroggAL, MahmoudRA, . Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry2002;63:920–30.
25.
GianfrancescoF, GroggA, MahmoudR, . Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther2003;25:1150–71.
26.
GianfrancescoF, WhiteR, WangR, . Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol2003;23:328–35.
27.
LundBC, PerryPJ, BrooksJM, . Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims based approach. Arch Gen Psychiatry2001;58:1172–6.
28.
KoroCE, FedderDO, L'ItalienGJ, . Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ2002;325:243–8.
29.
KornegayCJ, Vasilakis-ScaramozzaC, JickH.Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry2002;63:758–62.
30.
CitromeL, JaffeA, LevineJ, . Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv2004;55:1006–13.
31.
LambertBL, ChouCH, ChangKY, . Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf2005;14:417–25.
32.
WangPS, GlynnRJ, GanzDA, . Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol2002;22:236–43.
33.
SernyakMJ, LeslieDL, AlarconRD, . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry2002;159:561–6.
34.
LeeDW, FowlerRB, KadlubekPJ, . No significant difference in diabetes risk during treatment with typical versus atypical antipsychotics: results from a large observational study. Behavioral Health Trends2002;14(Nov):46–52.
35.
CitromeLL, JaffeAB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother2003;37:1849–57. DOI 10.1345/aph.1D142
36.
GrillV, PerssonG, CarlssonS, . Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects. Diabetologia1999;42:15–23.
37.
ShaiI, JiangR, MansonJE, . Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care2006;29:1585–90.
38.
ColditzGA, WillettWC, RotnitzkyA, . Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med1995;122:481–6.
39.
MillarWJ, YoungTK. Tracking diabetes: prevalence, incidence and risk factors. Health Rep (Statistics Canada, Cat 82–003)2003;14(3):35–47.
40.
GeissLS, PanL, CadwellB, . Changes in incidence of diabetes in US adults, 1997–2003. Am J Prev Med2006;30:371–7.
41.
Canadian Diabetes Association, Clinical Practice Guidelines Expert Committee.CDA 2003 clinical practice guidelines for the prevention and management of diabetes: screening and prevention. Can J Diabetes2003;27(suppl 2):S10–3.
42.
NarayanKM, BoyleJP, ThompsonTJ, . Lifetime risk for diabetes mellitus in the United States. JAMA2003;290:1884–90.
43.
LiebermanJA, StroupTS, McEvoyJP, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med2005; 353:1209–23.
44.
CitromeL, StroupTS. Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?Int J Clin Pract2006;60:933–40.
45.
McEvoyJP, MeyerJM, GoffDC, . Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res2005;80:19–32.
46.
NasrallahHA, MeyerJM, GoffDC, . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATTE schizophrenia trial sample at baseline. Schizophr Res2006;86:15–22.
47.
KollerEA, SchneiderB, BennettK, . Clozapine-associated diabetes mellitus. Am J Med2001;111:716–23.
KollerEA, WeberJ, DoraiswamyPM, . A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry2004;65:857–63.
51.
HedenmalmK, HaagS, StahalM, . Glucose intolerance with atypical antipsychotics. Drug Saf2002;25:1107–16.
52.
GurwitzJH, BohnRL, GlynnRJ, . Glucocorticoids and the risk of initiation of hypoglycemic therapy. Arch Intern Med1994;154:97–101.
53.
WrightAD, BarberSG, KendallMJ, . Beta-adrenoreceptor–blocking drugs and blood sugar control in diabetes mellitus. BMJ1979;1:159–61.
54.
CitromeL, JaffeA, LevineJ, . Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997–2004. Psychiatr Serv2006;57:1132–9.
55.
AmmonHP, OrciL, SteinkeJ.Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther1973;187:423–9.
56.
EnglJ, LaimerM, NiederwangerA, . Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry2005;10:1089–96.
57.
ChiuCC, ChenKP, LiuHC, . The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol2006;26:504–7.
58.
BeckleyET. New ADA initiative moves beyond 'metabolic syndrome.' DOC News 2006;3(July 1):1.
